Organon & Co.: Bipolar Disorder trials
The registry lists 10 Bipolar Disorder studies with Organon & Co. as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 3 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)CompletedNCT01349907Phase 3Results posted
- Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)CompletedNCT01244815Phase 3Results posted
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)CompletedNCT00159783Phase 3Results posted
- 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)CompletedNCT00145509Phase 3Results posted
- 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)CompletedNCT00145470Phase 3Results posted
- An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)CompletedNCT01498770
- Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)CompletedNCT01495741
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)CompletedNCT00159796Phase 3
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)CompletedNCT00159744Phase 3
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)CompletedNCT00143182Phase 3